SCHEMBL321434

SCHEMBL321434

CCOC(=O)c1c[nH]c2ccc(C(=O)c3c(C)cc4ccccn34)cc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ GABRA1 P14867 3/20 0.54
▸ GABRB2 P47870 3/20 0.54
▸ GABRB1 P18505 2/20 0.54
▸ GABRA3 P34903 2/20 0.54
▸ MAPT P10636 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ POLB P06746 1/20 0.47
▸ LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321292 0.82 ALDH1A1 (0.52) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL320313 0.81 L3MBTL1 (0.48) L3MBTL1MEN1ALDH1A1HPGDKMT2A
SCHEMBL2939048 0.76 HSD17B10 (0.81) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL11571896 0.75 MEN1 (0.72) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL7284420 0.73 GABRA1 (0.78) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL30417619 0.73 GABRA1 (0.78) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL376662 0.72 GABRA1 (0.69) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL29475801 0.72 GABRA1 (0.69) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL14842573 0.72 HSD17B10 (1.00) L3MBTL1MEN1ALDH1A1TP53HPGD
SCHEMBL7291769 0.72 GABRA1 (1.00) L3MBTL1MEN1ALDH1A1TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 L3MBTL1 2551/4885MEN1 1964/4885ALDH1A1 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback